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Abstract
Background: There is little information on how target lipid levels can be achieved in end stage
renal disease (ESRD) patients in a systematic, multidisciplinary fashion.
Methods:  We retrospectively reviewed a pharmacist-directed hyperlipidemia management
program for chronic hemodialysis (HD) patients. All 26 adult patients on chronic HD at a tertiary
care medical facility were entered into the program. A clinical pharmacist was responsible for
laboratory monitoring, patient counseling, and the initiation and dosage adjustment of an
appropriate 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin)
using a dosing algorithm and monitoring guidelines. The low-density lipoprotein (LDL) cholesterol
goal was ≤ 100 mg/dl. A renal dietitian provided nutrition counseling and the nephrologist was
notified of potential or existing drug interactions or adverse drug reactions (ADRs). Patients
received a flyer containing lipid panel results to encourage compliance. Data was collected at
program initiation and for 6 months thereafter.
Results: At the start of the program, 58% of patients were at target LDL cholesterol. At 6 months,
88% had achieved target LDL (p = 0.015). Mean LDL cholesterol decreased from 96 ± 5 to 80 ± 3
mg/dl (p < 0.01), and mean total cholesterol decreased from 170 ± 7 to 151 ± 4 mg/dl (p < 0.01).
Fifteen adjustments in drug therapy were made. Eight adverse drug reactions were identified; 2
required drug discontinuation or an alternative agent. Physicians were alerted to 8 potential drug-
drug interactions, and appropriate monitoring was performed.
Conclusions: Our findings demonstrate both feasibility and efficacy of a multidisciplinary approach
in management of hyperlipidemia in HD patients.
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Background
Patients on dialysis have more coronary artery disease
(CAD) and CAD-related mortality than the general popu-
lation [1]. Elevated low-density lipoprotein (LDL) choles-
terol level is an independent risk factor for patients with
end stage renal disease (ESRD) [2]. The 3-hydroxy-
3methylglutaryl coenzyme A (HMG-CoA) reductase in-
hibitors (statins) have been associated with decreased all-
cause mortality in dialysis patients in a registry-based
study [3] and clinical trials are underway to confirm this
benefit [4,5].
Mortality benefits of statins has been attributed to lower
lipid levels, but recent reports indicate that statins may re-
duce cardiovascular risk by other mechanisms, [6,7] and
may also reduce cancer-related mortality [8]. Consensus is
growing for statin use in all ESRD patients with athero-
sclerotic disease or diabetes [9]. If used this way, over 60%
of all dialysis patients might be eligible for statins [10].
Despite an acceptable safety profile [6,11], fewer than
10% of dialysis patients were prescribed statins according
to USRDS and Canadian studies, [3,12] even in known
coronary heart disease [13].
Despite differences in the pattern of dyslipidemia and car-
diovascular disease in ESRD patients compared with the
general population, current use of statins focus on treating
elevated LDL cholesterol levels. National Cholesterol Ed-
ucation Program (NCEP) guidelines recommend a target
LDL cholesterol of 100 mg/dl in high-risk groups [14].
Pharmacists are becoming more involved in managing a
variety of chronic diseases [15–19]. For lipid lowering, a
team approach is more effective in the ambulatory care
setting than management by a physician [20,21], but
there are no published reports on using this approach in a
dialysis population. Here, we describe the effectiveness
and feasibility of our multidisciplinary lipid management
program using the specific skills of pharmacist, dietitian
and nephrologist in hemodialysis patients.
Walter Reed Army Medical Center (WRAMC) is a 235-bed,
tertiary-care military hospital with 25–30 chronic dialysis
patients. Prior to implementation of our program, two
formulary statins (simvastatin and cerivastatin) were
available. A hospital-wide switch to these statins was man-
dated by the Department of Defense Pharmacoeconomic
Center to reduce cost and provide uniformity. A Statin
Formulary Conversion Clinic switched all patients to ce-
rivastatin (preferred agent) or simvastatin between Janu-
ary-April 2000 [22]. HD patients were given simvastatin
during the conversion due to dose adjustment recommen-
dations for cerivastatin in patients with renal insufficiency
and lack of experience with this drug in ESRD. Conse-
quently, there were several dialysis patients taking non-
formulary statins when our HD lipid management pro-
gram began, because they had failed to reach goals on for-
mulary statins.
Our program was designed as an ongoing lipid manage-
ment program, directed by the clinical pharmacist as-
signed to the Nephrology Service. The clinical pharmacist
received approval from the hospital credentials commit-
tee, the pharmacy & therapeutics committee, and the di-
rector of dialysis to prescribe and make dosage
adjustments and order laboratory tests as per a lipid man-
agement guideline. The WRAMC Human Use Committee
approved a 6-month retrospective review of the program
in April 2001.
Methods
Guideline development
A guideline for management of hyperlipidemia and con-
version to formulary statin in HD patients was developed
jointly between the nephrologists, clinical pharmacist and
renal dietitian before program implementation (Table 1).
Patients were converted at the start of the program, or
whenever they initiated dialysis. Only simvastatin and
atorvastatin were included in the guideline. Atorvastatin
was prescribed for patients who failed simvastatin.
Inclusion/exclusion criteria
All WRAMC chronic hemodialysis patients were eligible.
Exclusion criteria included age < 18 years, acute renal fail-
ure, pregnancy or nursing, use of cyclosporine, tac-
rolimus, or gemfibrozil, elevated liver associated enzymes
(LAEs), and allergy to statins. All 25 hemodialysis patients
met criteria for inclusion in September 2000 when the
program was implemented. An additional patient who in-
itiated dialysis during the study period was included, for a
total of 26 patients.
Laboratory monitoring
Blood tests were routinely drawn every 4 weeks for moni-
toring of anemia, calcium and phosphate control, LAEs,
nutritional indices, and dialysis adequacy. The pharmacist
ordered a non-fasting lipid profile for each patient in ac-
cordance with the guideline (e.g. every 8 weeks, every 4
months, or yearly depending on monitoring require-
ment). The lipid profile included total cholesterol (TC),
LDL cholesterol, triglycerides, and high-density lipopro-
tein (HDL) cholesterol. Blood was analyzed in the
WRAMC clinical chemistry laboratory using the Roche
COBAS Integra 700 System® (Roche Diagnostic System,
Somerville, NJ). Roche Precinorm® and Precipath® rea-
gents were used for quality control for HDL and LDL cho-
lesterol results. Bio-rad Liquicheck® Level 1 and Level 2,
(Bio-rad Diagnostic Group, Irvine, CA), were used for
quality control of TC and triglyceride measurements. Cal-
ibration was done daily. A non-fasting lipid profile was ac-
ceptable for LDL cholesterol and TC measurementBMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/9
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because the assay measured parameters directly. If the
non-fasting triglyceride level was ≥ 200 mg/dL, the physi-
cian was notified, and a fasting triglyceride level was or-
dered at his/her discretion.
Patient counseling and referral
After review of each lipid profile, the pharmacist provided
verbal instruction, statin information handouts (at drug
initiation or change), and a "Personal Cholesterol Man-
agement Report" to each patient. This reported the pa-
tient's own lipid profile result and goal values, as well as
the new statin dose (or dose to be continued). This report
also explained the importance of cholesterol control and
listed common side effects of statins. At the time of each
report, the pharmacist explained the lipid profile results,
asked about side effects, and reviewed the patient's drug
regimen for medication compliance and new or potential
drug interactions. The pharmacist also gave the patient a
new prescription with refills to last until the next sched-
uled lipid panel. Patients needing dietary reinforcement
were referred to the renal dietitian. Adverse reactions or
potential drug interactions were brought to the nephrolo-
gist's attention.
Documentation and data collection
The clinical pharmacist documented all interventions and
referrals using an Excel®  spreadsheet (Microsoft, Red-
mond, WA). Individual reports were generated that gave
lipid profile and LAE results, any adverse drug reaction or
drug interaction, dosage adjustments made, and the date
of the next scheduled lipid profile. This report was placed
in the patient's HD chart after each lipid profile. A copy
was given to each nephrologist.
Lipid data was tabulated monthly by the pharmacist and
submitted to the nephrology service quality improvement
coordinator, the medical director of dialysis, and the chief
of nephrology for ongoing program evaluation. Data sub-
mitted included the number of patients followed, number
of patients at LDL cholesterol goal, average LDL cholester-
ol and total cholesterol, number of adverse drug reactions
and potential drug interactions identified. HDL data was
not analyzed or included as part of the guideline.
Statistical analysis
Data was tabulated in Microsoft Excel® and analyzed using
SigmaStat® (SPSS, Chicago, IL). Fisher exact test was used
for categorical variables and paired Student's t-test was
used for continuous parametric variables. Wilcoxon
signed-rank test was used for continuous variables that
Table 1: Guideline for lipid management & conversion to formulary statin
a. Order lipid panel and P3* every 4 months if patient is currently on cholesterol lowering medication. 
b. If patient is at goal without drug therapy, draw lipid panel and P3 yearly.
c. Modify/Initiate patient's therapy per the following guideline:
If patient is on: Action:
Cyclosporine Refer to nephrologist
Gemfibrozil Refer to nephrologist
If triglycerides >200 Refer to nephrologist
If patient's current cholesterol medication is:
None, and LDL>100, no contraindications Begin Simvastatin 20 mg (1/2 of 40 mg tablet)
Provide pharmacy counseling, drug literature, dietary consult if 
needed.
Pravastatin, fluvastatin, lovastatin, simvastatin 5 mg, or simvastatin 10 mg qd Convert to Simvastatin 20 mg qd (1/2 of 40 mg tablet)
Atorvastatin 20 mg qd Convert to Simvastatin 40 mg qd
Atorvastatin 40 mg qd Convert to Simvastatin 80 mg qd
Atorvastatin 80 mg qd Continue Atorvastatin 80 mg qd
d. Draw P3 and lipid panel 8 weeks after changing or initiating therapy. 
If liver enzymes are >3 times upper limit of normal Refer to nephrologist.
Hold Statin.
If patient complains of muscle aches or weakness Refer to nephrologist.
Draw CPK.
e. If LDL>100 after 8 weeks, adjust dosing according to the following guideline:
If current dose is Simvastatin 20 mg qd Increase to Simvastatin 40 mg qd
If current dose is Simvastatin 40 mg qd Increase to Simvastatin 80 mg qd
If current dose is Simvastatin 80 mg qd Change to Atorvastatin 80 mg qd
f. Repeat steps d. and e. until patient reaches LDL goal or is taking Atorvastatin 80 mg
g. Draw P3 and lipid panel 8 weeks after initiating Atorvastatin 80 mg. If patient still not at LDL goal, refer to nephrologist.
*P3 includes alkaline phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubinBMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/9
Page 4 of 7
(page number not for citation purposes)
were not normally distributed. A p-value of < 0.05 was
considered statistically significant.
Results
Patient demographics are shown in Table 2. After 6
months, 23 of 26 patients (88%) had reached target LDL
cholesterol (Figure 1), compared with 15 patients (58%)
at the start of the program (p = 0.015). Mean LDL choles-
terol decreased 16.7%, from 96 ± 5 to 80 ± 3 mg/dl (p <
0.001), and mean total cholesterol decreased 11.1%, from
170 ± 7 to 151 ± 4 mg/dl (p = 0.004).
Eight adverse drug reactions were identified in 7 patients.
Four patients (15.4%) experienced musculoskeletal symp-
toms, 2 of which had muscle aches and weakness (hand,
arm and back muscles). Creatine phosphokinase (CPK)
levels were normal in both cases. Drug therapy was not in-
terrupted in either case, and other etiologies for the symp-
toms were pursued. The other 2 patients reported
shoulder soreness, thought related to exercise, and leg
cramping, thought to be due to the previous day's dialysis.
CPK levels were not obtained and the symptoms sponta-
neously resolved after several days.
Two patients (7.6%) experienced an increase in LAEs. A 3-
fold increase in serum transaminases occurred in one pa-
tient who was initiated on simvastatin 20 mg qd during
the program. The drug was discontinued. One patient had
a mild transient increase in alkaline phosphatase, from
115 IU/L to 131 IU/L, when starting statin therapy. The
drug was not discontinued and the level returned to base-
line within 2 months.
Diarrhea or gastrointestinal upset was reported in 2 pa-
tients (7.6%). Relationship to the statin was unclear. One
patient was switched from simvastatin to atorvastatin
with slight improvement. In the second patient, symp-
toms resolved when acetaminophen with codeine was
discontinued.
Eight potential drug interactions were identified. Physi-
cians were alerted to monitor for myopathy and changes
in international normalized ratio (INR) in 3 patients tak-
ing warfarin because of potential for cytochrome P450
3A4 competition. Other drugs with cytochrome P450 in-
teraction potential were identified, including verapamil
(2 patients), and diltiazem (1 patient). Other drug inter-
actions of a different/unknown mechanism included dig-
oxin and levothyroxine (1 patient each). No drug
interaction resulted in an adverse event or discontinua-
tion of therapy.
Fourteen patients (54%) were on statins at the start of the
program, 4 of whom were receiving non-formulary stat-
ins. (1 cerivastatin: 3 pravastatin.) Four patients were on
simvastatin 20 mg qd; 6 patients were on simvastatin 40
mg qd. At 6 months, 15 (58%) were on statins. Of these,
7 patients were on simvastatin 20 mg qd, 3 patients were
on simvastatin 40 mg qd, and 2 patients were taking sim-
vastatin 80 mg qd. One patient each was taking atorvasta-
tin 40 mg qd and 80 mg qd. Two patients were initiated
on statins during the period studied, one of which was
discontinued at 6 months due to increased LAEs. During
the 6-month period, 1 patient died from cardiovascular
disease. Her LDL cholesterol and TC were not elevated (55
mg/dl and 146 mg/dl, respectively). Three patients re-
ceived renal transplants.
Table 3 summarizes the interventions made by the phar-
macist. All patients received medication teaching and
compliance assessment at each encounter. Most patient
encounters resulted in continuation of current therapy
Figure 1
Change in LDL cholesterol 6 months after program initiation.
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Table 2: Patient Demographics (n = 26)
Mean age (years) 55.7 + 11
Gender (M/F) 17 / 9
Race (n, %)
Black 21 (81)
White 3 (11)
Asian 2 (8)
Etiology of chronic renal failure* (n, %)
Diabetes mellitus 11 (42.3)
Glomerulonephritis 9 (34.6)
Unknown or other 5 (19.2)
Hypertension 3 (11.5)
Median time on dialysis (months) 14.5 (range 0–153)
*totals >100% due to 2 patients with combined etiology of diabetes 
mellitus and hypertensionBMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/9
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(including those who were at goal LDL cholesterol with
non-pharmacological therapy). Statins were stopped in 1
patient because of low LDL cholesterol level (37 mg/dl).
The renal dietitian was consulted 3 times for specific die-
tary counseling relating to cholesterol control and compli-
ance.
Overall nutritional status remained stable. Median albu-
min at study entry was 3.73 g/dL (range 2.3 – 4.5 g/dL),
vs. 3.86 g/dL (range 2.9 – 4.7 g/dL) at 6 months (p =
0.345).
Discussion
This study shows that improved LDL cholesterol control
can be achieved in chronic HD patients using a multidis-
ciplinary pharmacist-directed lipid program. Hemodialy-
sis populations may be ideal for this program because of
convenient blood sampling and frequent provider con-
tact. Program costs included the minimal cost of patient
pamphlets, and the cost of additional pharmacist time.
We estimated that 8–12 additional hours/month were re-
quired for pharmacist interventions, documentation and
compiling reports. The program did not incur additional
laboratory costs, since lipid-monitoring guidelines were
those of the NCEP. Overall, the program was well accept-
ed by nurses, nephrologists and patients.
Side effects were minimal during the period, and several
potential drug interactions were avoided. Saltissi, et al
[11] recently reported the tolerability and effectiveness of
simvastatin in doses of 5–20 mg in lowering LDL and
non-HDL cholesterol in dialysis patients. Although the
majority of our patients required simvastatin 20 mg to
reach LDL goal, simvastatin in higher doses and atorvasta-
tin were used and well tolerated, with dose changes made
in a timely fashion, undoubtedly contributing to program
effectiveness. It is unknown whether a longer treatment
period with these doses would have produced more side
effects. One complicating factor of statin therapy in HD
patients is the high prevalence of hepatitis B and C, mak-
ing it difficult to differentiate hepatitis-induced increases
in LAEs from those due to the statin. This was not an issue
in our study, although several patients were positive for
hepatitis. Although CPK levels were not measured at base-
line, in patients with musculoskeletal symptoms, this val-
ue was found to be normal. Of note, the 3 patients who
did not reach LDL cholesterol goal were not those who ex-
perienced side effects requiring discontinuation of thera-
py. LDL levels in these patients were near goal and ranged
from 102–105 mg/dl.
Limitations of the study include the small number of pa-
tients and lack of a control group. Since patients began the
program after "physician only" lipid management, one
presumes by the improvement in lipid levels and number
of patients at LDL cholesterol goal that the team approach
was more favorable. That 54% of patients were on statins
and 58% were at goal LDL cholesterol at the beginning of
the program can be attributed to the close monitoring by
nephrologists in a fellowship program and the pharmacy-
run statin conversion clinic. Even so, these results im-
proved after implementing the multidisciplinary ap-
proach.
Although compliance was not documented by pill count,
the pharmacist, with access to computer databases, as-
sessed drug adherence by refill frequency, patient inter-
views, and lab results. In addition to increasing
compliance, including patients in therapeutic decision-
making may be cost-effective [23]. The patient handouts
with lipid results were well received and may have im-
proved patient's compliance and interest in lipid therapy,
but we did not formally assess patient knowledge of hy-
perlipidemia goals, treatment, and side effects, nor docu-
ment refill frequency.
Some studies suggest that dialysis patients with low LDL
cholesterol levels have increased risk of mortality vs. those
with higher LDL cholesterol levels [24]. LDL cholesterol
and conventional cardiac risk factors are insensitive pre-
dictors of CAD in this population [25], and may reflect
the high frequency of malnutrition [26] and established
cardiovascular disease [27]. In our study, albumin re-
mained stable as LDL cholesterol levels declined.
Although the guidelines for lipid therapy in HD patients
are extrapolated from the general population, current rec-
ommendations are to treat high-risk patients to a target
LDL cholesterol of ≤ 100 mg/dl. Most dialysis patients in
the United States do not meet these targets. Tonelli et al
[16] measured statin use in dialysis patients, but not
whether target LDL cholesterol was achieved. Admittedly,
lipid lowering and its benefits are less well defined in re-
nal failure explaining why nephrologists may not be as ag-
gressive in statin prescribing [28]. However, the
anticipated shortages of nephrology manpower (nephrol-
ogists, nurses, physicians' assistants, dietitians) may make
Table 3: Type of intervention by pharmacist
Type of intervention number
Continue current therapy 59
Change of therapy 15
Increase in dose (same drug) 6
Change drug 5
Initiation of therapy 2
Drug discontinued due to ADR 1
Drug discontinued (other) 1
Request dietary consult 3BMC Nephrology 2002, 3 http://www.biomedcentral.com/1471-2369/3/9
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it more difficult in the future to achieve therapeutic goals
[29]. Methods to help promote appropriate use of statins
and other drug therapy would be beneficial. Pharmacists
are not routinely assigned to dialysis units, however,
Manley, et al [30] showed that every dollar spent on phar-
maceutical care in ESRD results in a savings of $3.98. A re-
cent American College of Physicians-American Society of
Internal Medicine position paper speculates that pharma-
cist participation in patient care beyond patient education
and hospital rounds will be time consuming for physi-
cians [31]. In reality, pharmacist participation in the col-
laborative management of conditions such as
hyperlipidemia through programs like ours, may free ne-
phrologists' time for other activities and improve patient
outcomes while still maintaining physician control of
therapy. Yet, maintaining good communication, docu-
mentation, and quality assurance is essential.
The treatment of hyperlipidemia is readily suited to the al-
gorithmic, multidisciplinary approach used in the present
study. Moreover, similar programs could be employed for
management of other ESRD complications, such as hyper-
phosphatemia and anemia, further improving outcomes
in dialysis patients with the least possible impact on staff-
ing and resources.
Despite editorial speculation that nephrologists are "late
to the party" in adoption of cardiovascular risk reduction
measures [9], underutilization of proven therapies is not
unique to nephrology. The National Academy of Science's
Institute of Medicine reported that our health care deliv-
ery system continues to suffer from many deficiencies,
such as use of beta-blockers in only 50% of patients with
myocardial infarction [32]. The percentage in dialysis pa-
tients is similar [2]. Setting targets and achieving them are
quite different things. Undoubtedly, new methods for as-
suring the implementation of proven or therapies are
needed. The present study adds new information on the
process of improving statin use and other therapies that
could improve outcomes in dialysis patients.
Conclusions
Text for this section.
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